Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Management of Insomnia01:19

Management of Insomnia

499
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
499
Insomnia01:27

Insomnia

380
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
380
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

477
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
477
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

1.3K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
1.3K
Insufficient Sleep and Sleep Deprivation01:13

Insufficient Sleep and Sleep Deprivation

805
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
805
Narcolepsy01:07

Narcolepsy

463
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
463

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying major life events associated with insomnia disorder: Stressors that disrupt safety, stability, and identity.

Sleep health·2026
Same author

Discrepancies Between Subjective and Objective Evaluation of Sleep: Potential Marker for Mild Cognitive Impairment.

Sleep medicine research·2026
Same author

Solubility, speciation and thermodynamics of Fe in reducing aqueous KCl solutions.

RSC advances·2025
Same author

Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of Narcolepsy.

Journal of sleep research·2025
Same author

A randomized controlled trial of telemedicine CBTI and PUMAS for prenatal insomnia: Reducing nocturnal cognitive arousal is a treatment mechanism for alleviating insomnia and depression during pregnancy.

Sleep medicine·2025
Same author

A Mechanistic study assessing difficulty discontinuing chronic hypnotic use.

Psychopharmacology·2025

Related Experiment Videos

Insomnia: pathophysiology and implications for treatment.

Thomas Roth1, Timothy Roehrs, Ron Pies

  • 1Sleep Disorders and Research Center, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA. troth1@hfts.org

Sleep Medicine Reviews
|December 19, 2006
PubMed
Summary

Primary insomnia may be linked to major depressive disorder due to overactivity in the hypothalamic-pituitary-adrenal (HPA) axis and corticotropin-releasing factor (CRF). This suggests potential new treatments for insomnia targeting these pathways.

Related Experiment Videos

Area of Science:

  • Neuroendocrinology
  • Sleep Medicine
  • Psychiatry

Background:

  • Growing interest in understanding primary insomnia pathophysiology.
  • Evidence suggests similarities between primary insomnia and major depressive disorder.
  • Abnormal corticotropin-releasing factor (CRF) activity is implicated in major depression.

Purpose of the Study:

  • To explore the link between primary insomnia and mood disorders.
  • To investigate the role of the hypothalamic-pituitary-adrenal (HPA) axis and CRF in primary insomnia.
  • To identify potential therapeutic targets for chronic primary insomnia.

Main Methods:

  • Review of recent evidence on neuroendocrine and clinical similarities.
  • Analysis of findings related to corticotropin-releasing factor (CRF) activity.
  • Examination of hypothalamic-pituitary-adrenal (HPA) axis function in insomnia and depression.

Main Results:

  • Primary insomnia shares neuroendocrine and clinical similarities with major depressive disorder.
  • CRF hyperactivity appears to mediate hyperarousal in primary insomnia.
  • Evidence supports HPA axis overactivity and excess CRF, adrenocorticotropin releasing hormone, and cortisol secretion in primary insomnia.

Conclusions:

  • Primary insomnia is potentially linked with mood disorders.
  • HPA axis overactivity and excess CRF secretion are implicated in primary insomnia.
  • Antiglucocorticoid agents may offer a new management strategy for chronic primary insomnia.